GLP-1 inhibitors, like tirzepatide, show promise in reducing AHI in OSA patients with obesity, as demonstrated in the SURMOUNT trials. Experts highlight the importance of integrating GLP-1s with diet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback